NEW YORK, Feb.24 (GenomeWeb News) - In an agreement with non-profit CHDI, Cellumen will build a cellular model of Huntington's disease as the foundation of neurotoxicity profiling panel to characterize pre-clinical candidate models, Cellumen said yesterday.
The collaboration is expected to last about a year, Robert Pacifici of CHDI told GenomeWeb News.
"Cell-based phenotypic assays are critical for CHDI since there is not a clearly defined set of well-validated and chemically tractable targets for HD drug discovery," said Pacifici.
CHDI is the non-profit drug-discovery arm of the High Q Foundation for Huntington's disease.
Financial details were not released.